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Abstract
A growing body of evidence indicates that protein factors controlling translation play an important role in tumorigenesis.
The protein known as eIF6 is a ribosome anti-association factor that has been implicated in translational initiation and in
ribosome synthesis. Over-expression of eIF6 is observed in many natural tumours, and causes developmental and
differentiation defects in certain animal models. Here we show that the transcription of the gene encoding eIF6 is
modulated by the receptor Notch-1, a protein involved in embryonic development and cell differentiation, as well as in
many neoplasms. Inhibition of Notch-1 signalling by c-secretase inhibitors slowed down cell-cycle progression and reduced
the amount of eIF6 in lymphoblastoid and ovarian cancer cell lines. Cultured ovarian cancer cell lines engineered to stably
over-expressing eIF6 did not show significant changes in proliferation rate, but displayed an enhanced motility and invasive
capacity. Inhibition of Notch-1 signalling in the cells over-expressing eIF6 was effective in slowing down the cell cycle, but
did not reduce cell migration and invasion. On the whole, the results suggest that eIF6 is one of the downstream effectors of
Notch-1 in the pathway that controls cell motility and invasiveness.
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Introduction
The notion that the control of gene expression at the level of
translation is of considerable importance in tumorigenesis is
relatively new since several proto-oncogenes and tumour suppres-
sors have been shown to directly regulate ribosome production or
translation initiation altering the global translation rate and
inducing the translational enhancement or repression of specific
mRNAs [1]. The main mechanisms determining the pathological
perturbation of translation act at the level of a small set of protein
factors regulating translational initiation. Some of them, like eIF2
and eIF4E, are relatively well-characterized [2,3,4]. Moreover,
certain pathways that control ribosome biogenesis have also been
associated with the transformation process. For example, loss of, or
functional alterations in, the two major tumor suppressor proteins
pRB and p53 cause an up-regulation of ribosome biogenesis in
cancer tissues [5]. Likewise, depression of general translation in
transgenic mice haploinsufficient for ribosomal protein L24
suppresses the tumor-promoter activity of c-myc [6]. Recently,
another translational factor termed eIF6 has been identified as an
important player in translational regulation and cell-fate determi-
nation. eIF6 is a highly conserved protein shared by Eukaryotes
and Archaea that interacts with the large ribosomal subunits
regulating the formation of active 80S monosomes [7,8]. After its
initial identification as a ribosome anti-association factor, genetic
experiments in yeast led to its reclassification as a factor critically
involved in nucleolar rRNA processing and hence in the
biogenesis of 60S subunits [9]. Recent experiments in mammals,
including the production of eIF6 knock-out transgenic mice, have
however demonstrated that eIF6 has indeed a crucial role in
translation regulation, possibly in addition to a function in
ribosome synthesis [10]. Homozygous ablation of eIF6 determines
early lethality in mice embryos; heterozygous mice are, however,
viable, although having a reduced rate of protein synthesis.
Remarkably, eIF6 haplo-insufficient mice are resistant to myc-
induced lymphomagenesis [11]. In line with this result, eIF6
mRNA and protein overexpression has been observed in various
natural tumors [12,13]. In addition to a possible role in
tumorigenesis, eIF6 may be important in development and cell-
fate determination, as demonstrated by the fact that its altered
expression affects the development of X.laevis, presumably
inhibiting apoptosis [14,15].
In agreement with such apparent functional complexity, eIF6
expression appears to be highly variable between tissues and even
between individual cells in a tissue, with the highest levels observed
in epithelia and the lowest in muscle [16]. However, the factors
controlling eIF6 expression have not been studied in depth.
Intriguingly, the eIF6 promoter lacks a TATA box and contains
several GpC islands, features typical of housekeeping genes.
Earlier studies also provided evidence for the presence of serum-
responsive and NF-kB responsive elements, which were not
characterized further [16]. The hitherto best-characterized
regulator of eIF6 expression is the GABP complex, a global
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identify additional pathways involved in the transcriptional control
of the eIF6 gene. We found that eIF6 transcription is under the
control of the transmembrane receptor Notch-1, a protein
involved in a wide variety of human neoplasms [18], as well as
in embryonic development and cell differentiation [19]. In
particular, we demonstrate that eIF6 is a direct transcriptional
target of Notch-1 and that the control is performed, at least in
part, through RBP-Jk, a downstream modulator of Notch
signaling. Inhibition of Notch-1 signaling by c-secretase inhibitors
slowed down cell-cycle progression and decreased the level of eIF6
mRNA in cultured cells. Remarkably, over-expression of eIF6 in
stably transformed cell lines had little or no effect on cell
proliferation, but increased markedly cell migration and invasion.
On the whole, the results suggest that eIF6 is an important
downstream effector whereby Notch-1 modulates cell motility and
invasivity in physiological or pathological conditions.
Results
Notch1 inhibition promotes down-regulation of eIF6
expression in leukemic T cell lines
Overall, the eIF6 gene spans 5,520 base pairs and includes 6
introns and 7 exons. The starting ATG islocated inthe second exon,
while the first exon only contains 5’UTR elements. According to the
Ensemble database (ENST00000374450), the main transcription
start site of the eIF6 gene is located 498 nucleotides upstream of the
initiator ATG. To identify putative transcriptional control elements,
we screened about 2000 nucleotides (nt) upstream of the eIF6 gene
transcription start site using the Genomatix software. Among others,
we found two sequences (G/TGGGAA) at position 21464 and
2659 that fully matched the consensus-binding site of the factor
CSL(alsotermedRBP-JkandCBF-1inmammalsandSuppressorof
Hairless [Su(H)] in Drosophila), a known downstream effector of
Notch-1 signaling. Indeed, the best characterized mechanism by
which Notch activation controls transcription is by converting the
DNA-binding protein RBP-Jk from a transcriptional repressor into
an activator [20]. This finding suggested that the Notch signaling
pathway could be involved in the transcriptional control of the eIF6
gene, a particularly interesting possibility in the light of the fact that
Notch signaling has a pivotal role in development, differentiation
and proliferation.
To analyze the role of Notch signaling in the expression of eIF6,
three T-Cell leukemia-derived cell lines (Jurkat, SKW3 and
MOLT-3) known to carry gain-of-function mutations in Notch-1
[21] were treated with c-secretase inhibitors (GSI). C-secretases
trigger Notch signaling by cleaving and releasing the intracellular
domain of Notch (ICN), which then translocates to the nucleus
where it activates transcription. As shown in Fig. 1, treatment of all
three T-ALL cell lines for 16 hours with GSIs decreased
significantly the amounts of eIF6 mRNA, indicating that the
eIF6 gene is indeed a downstream target of Notch signaling.
Figure 1. Effect of GSI treatment on the expression of eIF6 and eIF4E. The different T-cell leukemia derived cell lines were treated with 5 mM
DAPT or control DMSO for 16h. Total RNA was isolated and expression levels of eIF6 (A) or eIF4E mRNA (B) were estimated by RT-PCR. The intensity of
the relevant bands was normalized with respect to the control GAPDH. The histograms represent the average of three independent experiments.
doi:10.1371/journal.pone.0032047.g001
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other translation initiation factors known to be involved in
translational control and tumorigenesis, the mRNA levels for
eIF4E were analyzed in Jurkat cells in the presence and in the
absence of GSI. As shown in Fig. 1B, Notch-1 inhibition did not
affect the transcription of eIF4E, suggesting that the Notch
receptor is not generally involved in regulating the expression of
translational factors.
Notch1-dependent expression of eIF6 involves direct
DNA-Binding of Notch1/RBP-jk to CSL elements in the
eIF6 regulatory region
As stated above, the eIF6 promoter contains two putative
binding sites for RBP-Jk, a well-known downstream effector of the
‘‘canonical’’ Notch signaling pathway (Fig. 2A). To address
whether Notch1/RBP-Jk directly associated with the eIF6
promoter, an electrophoretic mobility shift assay (EMSA) was
performed incubating nuclear extracts of Jurkat cells with
fragments of the eIF6 promoter.
The results, shown in Fig. 2B, revealed a clear shift only for the
fragment containing the 2659 putative RBP-Jk-binding site. The
shift was abolished by the addition of a 100/200-fold excess of
unlabeled probe, but not by the addition of a 100/200 fold excess
of non-specific unlabeled probe. Pre-incubation of the cell lysates
from Jurkat cells with RBP-Jk specific antibodies produced a
super-shift that revealed the presence of RBP-Jk in the complex
(Fig. 2B).
To further validate the above findings, chromatin immunopre-
cipitation (ChIP) assays were performed using anti-Notch-1
antibodies on Jurkat cell extracts. As Fig. 2C illustrates, the
specific antibodies, but not non-specific IgGs, were able to
immunoprecipitate chromatin enriched in eIF6 promoter se-
quence containing the RBP-Jk-binding element at position 2659.
In agreement with the EMSA assays, the region of eIF6 promoter
between the RBP-Jk-binding elements was not enriched in the
immuno-precipitates.
Activated Notch1 stimulates eIF6 promoter activity
through an RBP-Jk-dependent mechanism
The mechanism of Notch-1 transcriptional regulation of the
eIF6 gene was further investigated by performing luciferase
reporter assays. To this end, reporter plasmids were constructed
in which different fragments of the human eIF6 promoter (21765
to +227) were cloned upstream of the firefly luciferase gene
Figure 2. Analysis of RBP-Jk-binding sites in the human eIF6 promoter. (A) Shown is a diagram of the human eIF6 gene 59-flanking region
upstream from the first exon. The positions of putative RBP-Jk-binding sites (sites A–B) and of the PCR primers used in ChIP experiments (FR1 and
FR2) are indicated (black arrows). (B) EMSA were performed using nuclear extracts of the indicated cells and the labeled promoter fragment probes.
The arrow in all three panels indicates the position of the shifted site A fragment; the asterisk in the third panel indicates the position of the supershift
resulting from the addition of anti-RBP-jk antibodies. (C) ChIP assays. Chromatin from Jurkat cell extracts was immunoprecipitated with anti-Notch1
antibodies (N1 Ab) or with control rabbit IgG. The IPs were analyzed by PCR using primers specific for the indicated promoter regions of eIF6 or for
the Notch-binding region of the Hes1 promoter as the positive control.
doi:10.1371/journal.pone.0032047.g002
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NIH3T3 cells either without or with simultaneous co-transfection
with a plasmid expressing activated Notch-1 (N1). As shown in
Fig. 3B, co-transfection of eIF6-Luc/full-length (containing the
21765 to +227 promoter region including both the identified
putative RBP-Jk-binding elements) and activated Notch-1 resulted
in a about 2.5-fold increase in luciferase activity over the level
attained in absence of Notch-1. Similar levels of Notch-1
transcriptional stimulation were achieved with a reporter construct
containing only the RBP-Jk-binding element positioned at
2659 bp, further indicating that the distal putative RBP-Jk-
binding site is not involved in transcriptional modulation.
Accordingly, the construct containing only the 21464 RBP-Jk-
binding element was completely unresponsive to Notch-1. Similar
negative results were obtained with the reporter construct
containing the region between the RBP-Jk-binding elements. As
anticipated by the EMSA experiments, the transcriptional
stimulation of the eIF6 promoter by activated Notch-1 was
suppressed by the expression of a dominant-negative form of RBP-
Jk [22] which is unable to bind DNA but is able to interact with
Notch1 (Fig. 3C).
eIF6 over-expression enhances cell migration and
invasiveness without affecting proliferation
The data reported above suggested that eIF6 acted as a
downstream mediator of Notch-1 signaling. It is well established
that Notch signaling, besides being important for development and
differentiation, promotes survival and proliferation of many types
of cancer cells. For instance, T-ALL cells as well as ovarian cancer
cells are characterized by activated Notch signaling [21,23,24];
accordingly, down-regulation of Notch-1 by GSI contributes to
cell growth inhibition and apoptosis in ovarian cancer cells [23].
Notably, over-expression of eIF6 has been observed in a significant
proportion of ovarian serous adenocarcinomas and hematological
cancers [25]. To test whether the Notch-dependent stimulation of
cellular proliferation could be attributed, at least in part, to up-
regulation of eIF6 expression, A2780 ovarian cancer cell lines were
transformed with a plasmid expressing eIF6 from a strong
promoter. As shown in Fig. 4A/B, eIF6 stable clones had on
average 2-3-fold higher levels of eIF6 with respect to the controls,
whereas no clone producing the factor in really massive quantities
could be isolated, suggesting that a large excess of eIF6 is toxic for
the cells. Analysis of the polysomal profiles of the selected
Figure 3. Luciferase reporter assay. (A) Schematic representation of the region of the human eIF6 promoter containing two putative RBP-jk-
binding sites (sites A-B). Different tracts of the promoter were cloned upstream of the luciferase gene in the pGL3 Basic luciferase plasmid obtaining
the constructs indicated as FL, FR1, FR2 and FR3. (B) Luciferase assay. NIH-3T3 cells were cotransfected with Renilla luciferase plasmid and one of the
reporter plasmids shown in A in the presence (black columns) or the absence (grey columns) of a plasmid expressing human Notch-1 (N1). (C) NIH-
3T3 cells co-transfected with the FL plasmid and the N1 plasmid were further transfected with increasing amounts (0,25-0,5-1 mg) of a plasmid
expressing a dominant-negative form of RBP-jk (RBP-jk DN).
doi:10.1371/journal.pone.0032047.g003
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with the described anti-association activity of eIF6 on ribosomal
subunits [8]. However, the decrease of the 80S peak was
accompanied by an increase in the total amount of polysomes
(Fig. 4C), suggesting that a 2–3 fold over-expression of eIF6 had a
stimulatory effect on protein synthesis.
To investigate the impact of excess eIF6 on proliferation,
control and eIF6-expressing A2780 cells were cultured for 72 hrs
with or without added GSI and were then subjected to cell cycle
analysis. Without added GSI, both control and eIF6-expressing
cells had a similar distribution along the cell cycle, indicating that
the presence of excess eIF6 did not significantly affect proliferation
(Fig. 5, upper panels). Treatment with GSI of A2780-pCDNA3
control cells caused a dose-dependent induction of cell-cycle arrest,
evidenced by an increased proportion of cells in G1 phase and a
decrease in the proportion of cells in S phase. A similar arrest in
G1 following GSI treatment was also observed for the A2780-eIF6
cells, indicating that eIF6 is not sufficient to rescue the GSI
induced cell cycle arrest (Fig. 5, bottom panels). We also
performed colony-forming assays and found that clonal growth
of A2780 cells was not altered by eIF6 expression (data not shown).
In addition to affecting proliferation, the Notch pathway has
been reported to regulate motility and invasiveness of cancer cells
[26] Accordingly, we tested whether eIF6 overexpression had any
impact on the migratory and invasive capabilities of the A2780
cells, and whether these properties were affected by Notch
inhibition. To this end, trans-well migration and invasion assays
were performed with A2780 pCDNA3 control cells and A2780-
eIF6 cells, with and without treatment with GSI.
As shown in Fig. 6 (A,B), the A2780-eIF6 cells displayed a
markedly higher (about 40%) migratory capacity with respect to
the A2780-pcDNA3 cells, suggesting that over-dosage of eIF6
enhanced cell motility. Similar results were obtained when the
cells’ invasive capacity was tested by trans-well/matrigel assays
(Fig. 6 C,D): the A2780-eIF6 cells were about 20% more invasive
than the controls. That eIF6 indeed promoted a migratory and
invasive phenotype was confirmed by GSI-inhibition assays.
Strikingly, while the control cells showed, as expected, a reduction
in their capacity both to migrate to the bottom well and to degrade
the matrigel layer (25–35% compared to the DMSO), the A2780-
eIF6 cells were completely unaffected by GSI and remained highly
mobile and invasive (Fig. 6). Overall, the results suggest that eIF6
is implicated in the control of cell motility/invasiveness, and is one
of the downstream effectors whereby Notch signaling modulates
these cellular properties.
Discussion
Translation, long regarded as a rather dull cellular housekeep-
ing activity, is being increasingly recognized as an important
Figure 4. eIF6 expression in stably-transfected A2780 ovarian cancer cells. eIF6 expression in a pool of A2780 cells stably transfected with
the pcDNA3-eIF6 plasmid was analyzed by RT-PCR (A) and western blotting (B) as indicated. The intensity of the eIF6 RNA and protein bands was
quantified relative to b-actin and b-tubulin, respectively, using the ImageJ software. The results represent the average of three independent
experiments. (C) Analysis of the polysomal profiles of A2780/eIF6 and control cells by density gradient centrifugation. The areas under the polysomal
peaks were quantified using the ImageJ software.
doi:10.1371/journal.pone.0032047.g004
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been known for some time that certain translational factors,
notably eIF4E and eIF2, are downstream targets of various
signaling pathways that control cell proliferation [3,27,28]. Under
certain circumstances, an altered functioning of these factors can
steer the cell towards tumoral transformation. Recently, the
protein termed eIF6 has been added to the list of the translation
factors possibly involved in the control of cell proliferation. eIF6 is
a 27 kDa monomeric protein, first identified as a ribosome anti-
association factor [7] and later also implicated in the control of
ribosome synthesis [9]. Although eIF6 is an essential factor and its
deletion causes early embryonic lethality [10], its precise function
in translation (or in other cellular functions) remains elusive.
We show here that the transcription of the eIF6 gene is
regulated by the Notch-1 receptor, controlling an evolutionarily
conserved signal transduction pathway of paramount importance
in development, cell differentiation and proliferation [20].
Alterations in the Notch-1 pathway underlie many developmental
and differentiation defects, and are also observed in several types
of tumors [18]. We found that stable expression of eIF6 does not
significantly alter the rate of cellular proliferation, but has a
profound effect on cell motility/invasiveness. In A2780 ovarian
cancer cell lines, a 2–3 fold over-expression of eIF6 enhances the
cell invasive properties, and is moreover sufficient to rescue
completely the inhibition of migration and invasiveness caused by
treatment with GSI, suggesting that eIF6 is a main downstream
target of Notch signaling in the pathway controlling cell motility/
invasiveness. These results agree with previous data showing that
over-expression of eIF6 affects morphogenesis during D.melanogaster
development [29], that eIF6 phosphorylation and its association
with the cytoskeleton are developmentally regulated in X.laevis
[30], and that eIF6 is frequently over-expressed in several types of
metastatic tumors [13]. Therefore, our data indicate the possibility
that Notch/eIF6 axis could be responsible for the triggering, at
least in part, of metastatic mechanisms in the invasive cells.
It is noteworthy that only modest variations of the eIF6 cellular
levels seem to be able to significantly affect cell behavior. As we
show in this work, Notch-1 activation increases the transcription of
the eIF6 gene 2–3 fold. Induced over-expression of the protein
within a similar order of magnitude is sufficient to markedly
enhance cell motility and capacity to migrate through a matrigel
layer.
The mechanism whereby eIF6 affects cell motility/invasiveness
remains to be elucidated. The established function of eIF6 is on
protein synthesis and/or ribosome synthesis, but it is likely to act
on other cellular functions as well. Indeed, eIF6 has been shown to
bind to beta4-integrin and to be present at hemi-desmosomes,
suggesting a participation in cell-cell adhesion and communication
[31,32]. These cytoskeletal connections of eIF6, whose functional
significance is still unknown, are prime candidates to explain the
influence of the factor on cell migration and invasion. The
alternative possibility is that eIF6 may control, directly or
indirectly, the synthesis of some protein(s) involved in the control
of cell motility. For instance, abundance or dearth of eIF6 might
favor (or otherwise) the translation of specific mRNAs encoding
products important for cell motility. Some support for this
hypothesis comes from our observation that the A2780 cells
over-expressing eIF6 have a lesser amount of 80S ribosomes but
an increased amount of polysomes (Fig. 4). This suggests that a 2–3
fold increase in eIF6, as observed in this study, might exert a
Figure 5. eIF6 over-expression does not significantly affect cell cycle. FACS analysis of cell-cycle distribution of control (A) and eIF6-over-
expressing (B) A2780 cells grown for 72 h in the absence (top) or in the presence (bottom) of 75 mM DAPT.
doi:10.1371/journal.pone.0032047.g005
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initiation or by accelerating ribosome recycling. Such an effect
could in turn increase (or decrease) the translation rate of specific
mRNAs.
A still more intriguing possibility is that eIF6 controls the
abundance and/or translation of certain mRNAs by a microRNA-
mediated mechanism. In fact, it has been reported that eIF6
associates with the RISC and, in certain organisms at least, is
required for miRNA-mediated control of translation [33]. Much
more research is required to fully elucidate the cellular functions of
this very interesting factor.
Materials and Methods
Plasmids
Human eIF6 promoter (21754 to +227) was PCR amplified
using a proof reading Taq (Kapa HiFi) with the following primers
sense 59-GGACCTCATCACCAAGTATC-39 and antisense 59-
CTGTACCTTGGACTCCCTAA-39. The amplified product of
1992 bp was cloned by TA-vector kit (RBC Bioscience) and
successively inserted into pGL3 Basic luciferase plasmid (Promega)
using the XhoI-HindIII restriction sites. This luciferase reporter
construct, termed FL eIF6 prom-luc, was then used to generate the
subsequent three constructs for luciferase assays using the primers
summarized in Table 1.
To clone the human full-length eIF6 gene we used the following
primers: forward (59-CCCAAGCTTCTGGTTACTTGGCCT-
CAT-39) and reverse (59-CATGGTATGCTCGAGAATGTG-
GAGAAGGTTGGC-39). The resulting amplification product
was inserted at the HindIII-XhoI sites of pcDNA
TM 3.1(+) vector.
All plasmids were verified by DNA sequencing.
Cell transfection and luciferase assay
Transient transfection experiments were performed by Lipo-
fectamine 2000 kit (Invitrogen) according to manufacturer’s
instructions. NIH/3T3 cells, grown in DMEM supplemented
with 10% FBS and L-Glu 2%, were seeded in 24-well plates at a
density of 3610
5 cells per well. The day after cells were transfected
with the eIF6 promoter vectors (21754 to +227) as reporter
(0.5 mg) in presence or absence of the expression vector for human
Figure 6. Over-expression of eIF6 enhances migration and invasivity of ovarian cancer cells. (A, B) Migration assay: A2780/eIF6 and
control cells were treated with DAPT 75 mM or DMSO for 36 h then seeded in the upper side of migration chambers. The cells migrated to the lower
chambers after 36 h of incubation were stained with crystal violet dye. (C, D) Invasivity assay: cells were treated with DMSO or DAPT 75 mM for
36 hours and seeded in the upper side of invasion chambers. After 36 h, cells migrated in the lower chamber were stained. The total stained area in
the lower chambers was estimated using the Image-J software. The histograms in (B) and (D) represent the average of three independent
experiments. P values estimating the statistical significance of the observed experimental variations between different data sets (control cells with
and without GSI; eIF6 cells with and without GSI; control and eIF6 cells without GSI; control and eIF6 cells with GSI) are shown for both cell migration
and invasion experiments.
doi:10.1371/journal.pone.0032047.g006
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effector gene and pRL-CMV vector (10 ng) expressing Renilla
luciferase. pcDNA3 vector was used as an empty control vector
and was added to each sample ensure an equal amount of total
DNA.
The day after the cells were lysed using Dual-Luciferase/Renilla
Reporter Assay System (Promega, Madison, WI) reagents in
accordance with the manufacturer’s instructions.
Firefly- and pRL-TK-derived Renilla luciferase activities were
measured in each sample using a Triathler Multilabel Tester
(Beijing Huaruison Science and Technology Development Co.,
Ltd).
Polysomal profiles
A2780 and the corresponding stable eIF6 clone cells (about
5610
6 cells) were treated with cycloheximide (CHX) to a final
concentration of 100 mg/ml and then incubated at 37uC for
15 min. After washing the monolayer once with ice-cold PBS
1X+CHX (50 mg/ml), the cells were scraped in 500 ml of ice-cold
lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM KCl, 15 mM
MgCl2, 1 mM DTT, 1% Triton-X 100, 1% deoxycholate,
0,5 unitsml
21 rRNasin, 100 mg/ml CHX) for 5 min on ice. Cell
debrises were removed by a 8 min centrifugation at 10,000 g at
4uC. 30 A260 units of supernatants were layered on top of a linear
15–50% (w/v) sucrose gradient containing 20 mM Tris-HCl
pH 7.4, 5 mMMgCl2,140 mMKCl,0,5 mMDTTand0,1 mg/ml
CHX. The gradients were centrifuged at 4uC in a SW41
Beckman rotor for 2 h at 39,000 rpm and unloaded while
monitoring absorbance at 260 nm with the ISCO UA-5
absorbance instrument. Successively, the graphic of polyribo-
somal profiles was analyzed with the ImageJ software in order
to calculate the area under the peaks of interest.
Chromatin Immunoprecipitation (ChIP)
Protein complexes were cross-linked to DNA in living nuclei by
adding formaldehyde (Sigma, Inc.) directly to fresh Jurkat cell lines
to a final concentration of 1%. Crosslinking was allowed to
proceed for 10 min at 37uC and was then stopped by the addition
of glycine to a final concentration of 0.125 M. Cross-linked cells
were washed twice with phosphate-buffered saline and pelletted.
Nuclei were extract with a buffer containing 10 mM Tris pH 8,
0,25% Triton-X 100, 10 mM Na-EDTA, 0.5 mM Na-EGTA and
protease inhibitors, pelleted by microcentrifugation and lysed by
incubation in SDS lysis buffer (0.5% sodium dodecyl sulfate,
5 mM Na-EDTA, 50 mM Trischloride pH 8), containing prote-
ase inhibitors. The resulting chromatin solution was sonicated for
15 pulses of 15 s at 80% power to generate 300–1000 bp DNA
fragments. After microcentrifugation, the supernatant was diluted
1:5 with a dilution buffer (0.01% sodium dodecyl sulfate, 1%
Triton X-100, 1 mM EDTA, 20 mM Tris-chloride pH 8,
150 mM NaCl, containing protease inhibitors), and aliquoted.
After precleaning with Salmon Sperm DNA/Protein A agarose
(Upstate Biotechnology) 5 mg of antibodies anti-Notch-1 (C-20) or
normal rabbit IgG, (Santa Cruz Biotechnology Inc.) were added to
each aliquot of chromatin and incubated on a rotating platform
for 12–16 h at 4uC. Antibody–protein–DNA complexes were
isolated by immunoprecipitation with Salmon Sperm DNA/
Protein A agarose (Upstate Biotechnology). Following extensive
washing, bound DNA fragments were eluted and analyzed by
subsequent PCR with the following primers: CSL fragment
forward (59-CATGGTATGCTCGAGGCTGTGACAGGTTGT-
GGGCC-39), CSL fragment reverse (59-CCCAAGCTTCCAC-
GATGTGCCTCTCGC-39), intermediate fragment forward (59-
CATGGTATGCTCGAGCTGCTGGAGAAGGGGTCAG-39),
intermediate fragment reverse (59-CCCAAGCTTAGGATACAC-
CAGGCGCTG-39).
As the positive control, we performed PCR to amplify a
fragment of the Hes1 promoter known to bind Notch-1, using the
following primers: Hes1 promoter forward (59-CTGTGGGAAA-
GAAAGTTTGGG-39); Hes1 promoter reverse (59-GACCAAG-
GAGAGAGGTAGAC-39).
EMSA
The frozen cell pellet was thawed, resuspended at a concentra-
tion of 10 ml/10
7 cells in cold buffer C (Hepes 20 mM pH 7.9,
NaCl 0.4 M, EDTA 1 mM, EGTA 1 mM, DTT 1 mM, PMSF +
protease inhibitors 1 mM and 1% NP-40) and vortexed vigorously
for 2 min at 4uC. Debris was pelleted and the supernatant
removed as the whole-cell extract. EMSA were performed by
using double strand DNA obtained digesting WT eIF6 prom-luc
with AvaI or ApaLI-SpeI. The reaction products, DNA fragments
of 164 and 226 bp respectively, contained the CSL elements of our
interest. The fragments were purified from agarose gels by DNA
Fragment Extraction kit (RBC Bioscience). Successively, these
products were labeled with [a
32P]dCTP by Klenow enzyme
(Roche) and purified over a G25 sepharose column. The probe
(10 fmol) was incubated for 20 min at room temperature
Cell lines and treatments
Human T-lymphoblastic cell lines JURKAT, SKW3 and
MOLT3 and human ovarian cancer cell line A2780 were kept
in culture in RPMI 1640 (Gibco) supplemented with 10% FBS
(Gibco) and 1 mmol/L L-glutamine at 37uCi n5 %C O 2. Mouse
embryonic fibroblast cells NIH3T3 were kept in culture in
D-MEM (Gibco) supplemented with 10% FBS (Gibco) and
1 mmol/L L-glutamine at 37uCi n5 %C O 2. Whenever required,
a ˜-secretase inhibitor IX (GSI) (Calbiochem) or DMSO was added
at the concentration of 5ı `M to the growth medium of human
T-lymphoblastic cell lines JURKAT, SKW3 and MOLT3 for
16 h. In the experiments performed with A2780 cells, GSI was
used at the final concentration of 75 mM for 16 h. At the end of
incubation the cells were washed with PBS 1X and collected.
Total protein extract was obtained by lysing the cells with
extraction buffer (20 mM Tris-HCl pH7.5, 150 mM NaCl, 1 mM
EDTA pH8, 1% Triton-X and protease inhibitor cocktail)
(Roche).
Table 1. List of the primers used for the cloning of different
constructs.
Name
construct Primers
FR1
Forward 59-CATGGTATGCTCGAGGCTGTGACAGGTTGTGGGCC-39
Reverse 59-CCCAAGCTTCTGTACCTTGGACTCCC-39
FR2
Forward 59-CATGGTATGCTCGAGCCTGGGGGTCCCAAGGG-39
Reverse 59-CCCAAGCTTCTCCAGGACTCTCTGCCC-39
FR3
Forward 59-CATGGTATGCTCGAGCTGCTGGAGAAGGGGTCAG-39
Reverse 59-CCCAAGCTTAGGATACACCAGGCGCTG-39
The reaction sites used for the cloning are underlined.
doi:10.1371/journal.pone.0032047.t001
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16 hours prior to transfection, A2780 cells were seeded at 50%
confluence in 60 mm dish. Transfection was carried out according
to the manufacturer’s instructions of Lipofectamine 2000 (Invitro-
gen) using 5 mg of linearized human full-length eIF6 expression
vector or equal amounts of pcDNA3 as the control. After 24 h, the
cells were trypsinized and distributed over three 100 mm dishes
per well. Medium was replaced every three days with culture
medium containing 200 mg/ml of G418 (selection medium) until
clones formed which were large enough to isolate (about two
weeks). Selected positive clones were pooled and used for the next
experiments.
Migration assay
Cells were pretreated in complete medium containing 75 mMo f
GSI for 36 h before plating (2.5610
5 per well) in the BD Falcon
TM
Cell Culture Inserts (BD Biosciences). Mock treatments were
carried out pretreating the cells in the same medium with DMSO.
The chambers with the cells were placed on 24-well plates
containing medium without serum. In the lower chamber,
medium supplemented with 10% FBS was used as chemo-
attractant. After 36 hours, cells migrated to the lower chamber
were stained with crystal violet dye. The total stained area was
quantified using the Image-J software. Experiments were carried
out in triplicate and repeated three times. Statistical analyses were
performed using paired Student’s t test for independent samples.
Differences were considered significant if the probability (p) was
,0.05.
Invasion in Matrigel-coated chambers
Cells were pretreated in complete medium containing 75 mMo f
GSI for 36 h before plating (2.5610
5 per well) in the BD Matrigel
invasion chambers (BD Biosciences). Mock treatments were
carried out pretreating the cells in the same medium with DMSO.
Cells were seeded in the upper chamber in treatment medium
without serum. In the lower chamber, medium supplemented with
10% FBS was used as chemo-attractant After 36 hours, cells
migrated to the lower chamber were stained with crystal violet
dye. The total stained area was quantified using the Image-J
software Experiments were carried out in triplicate and repeated
three times. Statistical analyses were performed using paired
Student’s t test for independent samples. Differences were
considered significant if the probability (p) was ,0.05
RT-PCR
Human T-lymphoblastic cell lines JURKAT, SKW3 and
MOLT3 were treated in complete medium containing 5 mMo f
GSI for 16 h. Mock treatments were carried out treating the cells
in the same medium with DMSO. Total RNA was extracted from
cells using TriZol reagent (Invitrogen). One microgram of RNA
was used to generate cDNA using oligo dT (Applied Biosystem)
and M-MLV reverse transcriptase (Promega). Two microliters of
cDNA was used for PCR reactions. All reactions were carried out
for 25 cycles. Primer used for the analysis of eIF6 mRNA levels
were as follows: eIF6-PCR, forward 59- CAATGTCACCACCTG-
CAATG-39 and reverse 59-AGTCATTCACCACCATCCCA-39.
The primers used for the analysis of eIF4E mRNA levels were as
follows: eIF4E FW 59- GGAAACCACCCCTACTCCTA-39 and
eIF4E Rev 59- ATGGTTGTACAGAGCCCAAA-39.
All PCR products were analyzed on 1% agarose gel
electrophoresis. For calculating the expression level, the band
intensities of PCR products were measured using ImageJ (NIH)
software and normalized to that of GAPDH.
Flow cytometry and cell cycle analysis
The cell cycle was analyzed by flow cytometry. Cells (1610
6)
were collected and washed in PBS, then fixed in 75% alcohol for
30 min at 4uC. After washing in cold PBS three times, cells were
resuspended in 1 ml of PBS solution with 40 mg of propidium
iodide and 100 mg of RNase A for 30 min at 37uC. Samples were
then analyzed for their DNA content by FACSCalibur
TM (BD
Biosciencies). Each experiment was repeated three times.
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